Search Results - therapeutics

8 Results Sort By:
Bisphosphonate Conjugates with RON Kinase Inhibitors
Researchers at TGen and the University of Utah are developing bisphosphonate (diphosphonic acid) conjugates with RON kinase inhibitor compounds for treating metastatic cancers, such as breast cancer, and diseases, such as osteoporosis and osteoarthritis, associated with bone destruction.  These conjugated bisphosphonates combine the anti-mitotic, anti-angiogenic,...
Published: 3/2/2020   |   Inventor(s): Hariprasad Vankayalapati, Sunil Sharma, Alana Welm
Keywords(s):  
Category(s): Therapeutics, Chemicals, Biotechnology
TREM2 agonists for the preventative and therapeutic treatment of neugodegenerative disorders
Researchers at TGen have identified new potential preventative and therapeutic treatments for clinical management of Alzheimer’s disease and other neurodegenerative disorders with an immune neuorinflammatory component such as frontotemporal dementia, chronic traumatic encephalophathy, Down syndrome, or other diseases with an amyloid and/or tau neuropathy. ...
Published: 3/2/2020   |   Inventor(s): Matt Huentelman, Isabelle Schrauwen, Wayne Jepsen
Keywords(s):  
Category(s): Therapeutics
Repurposed Drugs for the Treatment of Fungal Infections Caused by Coccidioides
Researchers at TGen and Northern Arizona University (NAU) have developed an effective treatment for fungal infections caused by Coccidioides including the Valley Fever-causing species: Coccidioides immitis and Coccidioides posadasii in humans and companion animals (particularly canines).  Repurposed drugs originally developed to inhibit hormone uptake...
Published: 1/30/2019   |   Inventor(s): David Engelthaler, Elizabeth Driebe, Hongwei "Holly" Yin, Michael Valentine, Donald Chow, Jolene Bowers, Paul Keim
Keywords(s): Pathogens, Veterinary Medicine
Category(s): Therapeutics
Targeted Therapies for Cancers Containing NRG1 Fusions
Researchers at TGen, in collaboration with the Mayo Clinic, have identified a new method of targeted cancer treatment by selecting a patient population based on the presence of Neuregulin-1 (NRG1) somatic gene fusion events (i.e., NRG1 fusions).  Tumors of the patients in this identified population may be treated with targeted therapies, including Epidermal...
Published: 1/29/2019   |   Inventor(s): John Carpten, David Craig, Sara Byron, Jessica Aldrich, Keith Stewart, Mitesh Borad, George Vasmatzis, Michael Barrett, Alan Bryce
Keywords(s):  
Category(s): Therapeutics
Methods for identifying and treating pancreatic cancer with ROCK1 therapeutic target
Researchers at TGen have developed a method for identifying and treating pancreatic cancer.  Through the identification of the ROCK1 gene as a therapeutic target, pancreatic cancer can be detected and tumor cell proliferation and migration can be inhibited using the inventive methods.Pancreatic cancer is a prevalent cause of tumor related deaths in...
Published: 7/23/2018   |   Inventor(s): Haiyong Han, Clifford Whatcott, Daniel Von Hoff, Michael Barrett
Keywords(s):  
Category(s): Therapeutics
Soluable and Solid Forms of Curcumin for Pharmaceutical Application
Researchers at TGen have developed a curcumin-2-aminobenzimidazole co-crystal that is water soluble, non-hygroscopic, solid below 118° C, and chemically stable under a range of conditions, temperatures, humidity, ambient light and water with no signs of degradation, disproportion, or loss of crystallinity.Curcumin is a linear diarylheptanoid and is...
Published: 8/17/2017   |   Inventor(s): Steve Gately, Steven Triezenberg, Tong Wang
Keywords(s):  
Category(s): Therapeutics
NHERF-1 Protein Complexes, Cancer Progression and Therapeutic Targeting
Researchers at TGen have patented a method of detecting invasive glioblastoma in a subject and sensitizing the subject to a therapeutic treatment that targets non-migrating glioblastoma cells. Specifically, our researchers have discovered that Na+/H+ exchanger regulatory factor (NHERF-1) is over-expressed in invasive GBM cells and have confirmed its...
Published: 8/17/2017   |   Inventor(s): Michael Berens, Kerri Kislin
Keywords(s): Cancer & Cell Biology
Category(s): Therapeutics, Diagnostics
Methods for identification of compounds capable of selectively eliminating cancer cells with specific loss-of-function alterations
Summary of the InventionResearchers at TGen have patented a method for identifying molecules that reduce viability of cancer cells with a specific pattern of a loss-of-function genetic alteration. These molecules are identified by creating a matched pair of isogenic cell lines that differ only by a siRNA "knock down" of a single DPC4 gene. The matched...
Published: 8/17/2017   |   Inventor(s): Haiyong Han, Daniel Von Hoff, Hong Wang, Gary Flynn
Keywords(s):  
Category(s): Therapeutics